Holen Sie sich die Stockscreener-App
0.8633
1.56%
-0.0137
Vorhandelsmarkt:
.84
-0.0233
-2.70%
Schlusskurs vom Vortag:
$0.877
Offen:
$0.8945
24-Stunden-Volumen:
224.01K
Relative Volume:
0.79
Marktkapitalisierung:
$47.07M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
86.33
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
-0.77%
1M Leistung:
-20.06%
6M Leistung:
-32.02%
1J Leistung:
-41.67%
1-Tages-Spanne:
$0.85
$0.8989
1-Wochen-Bereich:
$0.7402
$0.9498
52-Wochen-Spanne:
$0.7402
$1.89
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Vergleichen Sie SPRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
0.8633 | 47.07M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Spero therapeutics director Ankit Mahadevia sells $53,990 in stock By Investing.com - Investing.com Australia
Spero Therapeutics CEO sells shares worth $121,159 - MSN
Spero therapeutics CFO sells $16,137 in stock - Investing.com India
Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN
Spero therapeutics director Ankit Mahadevia sells $53,990 in stock - Investing.com India
Spero Therapeutics Inc (SPRO) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily
Stock Market Recap: Spero Therapeutics Inc (SPRO) Concludes at 0.75, a -6.19 Surge/Decline - The Dwinnex
Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough - Simply Wall St
Spero Therapeutics’ (SPRO) Buy Rating Reiterated at HC Wainwright - Defense World
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts - Benzinga
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know - MSN
Spero Therapeutics stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Spero Therapeutics stock hits 52-week low at $0.92 - Investing.com India
TD Cowen Downgrades Spero Therapeutics (SPRO) - MSN
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin? - Marketscreener.com
Geode Capital Management LLC Decreases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Discloses Financial Estimates and Leadership Changes Amid SEC InvestigationOn January 7, 2025, Spero Therapeutics, Inc. (NASDAQ: SPRO) released a significant update and disclosed estimated financial information as of December 3 - Defense World
Spero Therapeutics, Inc. Announces CEO Changes - Marketscreener.com
Spero Therapeutics announces interim leadership amid SEC inquiry - Investing.com India
Spero Therapeutics announces interim leadership changes - TipRanks
Spero Therapeutics Faces SEC Probe and Leadership Changes - TipRanks
Spero Therapeutics names Esther Rajavelu as Interim President and CEO (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes - GlobeNewswire
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Cut to In-Line at Evercore ISI - Defense World
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
Spero Therapeutics (NASDAQ:SPRO) Lowered to In-Line Rating by Evercore ISI - MarketBeat
What 4 Analyst Ratings Have To Say About Spero Therapeutics - Benzinga
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Research Analysts Set Expectations for SPRO FY2024 Earnings - MarketBeat
Spero Therapeutics Q3 2024 Earnings Preview - MSN
Wainwright reiterates Buy rating on Spero Therapeutics with PIVOT-PO enrolment on track - Investing.com Canada
Carbapenem Market Size, Trends, Growth, Opportunities - openPR
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Spero Therapeutics' (SPRO) "Hold" Rating Reiterated at TD Cowen - MarketBeat
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Spero Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartzy
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):